## Gastric Carcinoma Pathogenesis: The Correa Cascade ### The Correa Cascade Model The Correa cascade is the gold-standard model explaining the stepwise progression from normal gastric mucosa to gastric adenocarcinoma, particularly the **intestinal type**. This patient's presentation—chronic atrophic gastritis, intestinal metaplasia, and intestinal-type adenocarcinoma—perfectly exemplifies this cascade. ### Sequential Steps in the Correa Cascade | Stage | Pathological Change | Duration | Key Features | |-------|---------------------|----------|---------------| | **1. Normal mucosa** | Normal gastric glands | — | Baseline | | **2. Chronic gastritis** | Inflammatory infiltrate (H. pylori, autoimmune) | Years to decades | Reversible if H. pylori eradicated | | **3. Atrophic gastritis** | Loss of glandular tissue, reduced acid secretion | Years to decades | Pernicious anaemia if autoimmune | | **4. Intestinal metaplasia** | Replacement of gastric mucosa by intestinal-type epithelium (goblet cells) | Years to decades | **Point of no return** — increased cancer risk | | **5. Dysplasia** | Low-grade or high-grade dysplasia; loss of normal architecture | Months to years | Requires surveillance | | **6. Adenocarcinoma** | Invasive malignancy, usually intestinal type | — | Established cancer | **Key Point:** This patient has **chronic atrophic gastritis** (evidenced by pernicious anaemia, a marker of autoimmune gastritis) and **intestinal metaplasia** (shown by the histology with well-formed glandular structures). The progression from metaplasia → dysplasia → adenocarcinoma is the classic Correa cascade and is the most common pathway to gastric cancer in high-risk populations. **High-Yield:** The **loss of CDX2 expression** noted in the immunohistochemistry is significant: - CDX2 is a transcription factor normally expressed in intestinal epithelium. - Loss of CDX2 in intestinal metaplasia is associated with **incomplete (Type III) intestinal metaplasia**, which has higher malignant potential than complete intestinal metaplasia. - This finding supports the diagnosis of intestinal-type adenocarcinoma arising from the metaplastic cascade. **Clinical Pearl:** Autoimmune atrophic gastritis (as in this patient with pernicious anaemia) carries a **2–3% lifetime risk of gastric cancer**, justifying endoscopic surveillance in these patients. H. pylori-associated atrophic gastritis carries an even higher risk. ### The Correa Cascade Flowchart ```mermaid flowchart TD A[Normal Gastric Mucosa]:::outcome --> B[Chronic Gastritis<br/>H. pylori or Autoimmune]:::action B -->|Reversible if H. pylori eradicated| C[Atrophic Gastritis<br/>Gland loss, hypochlorhydria]:::action C -->|Point of no return| D[Intestinal Metaplasia<br/>Goblet cells, CDX2+]:::action D -->|Increased cancer risk| E[Low-Grade Dysplasia]:::action E -->|Progression| F[High-Grade Dysplasia]:::action F -->|Inevitable if untreated| G[Adenocarcinoma<br/>Usually Intestinal Type]:::urgent H[Risk Factors] -->|Accelerate cascade| B I["Risk Factors:<br/>H. pylori<br/>Autoimmune gastritis<br/>Smoking<br/>Diet"] -.-> H ``` **Mnemonic: CAIN = Chronic gastritis → Atrophic gastritis → Intestinal metaplasia → Neoplasia (adenocarcinoma)** ### Why This Is the Correa Cascade and Not Other Pathways **Autoimmune (Type A) atrophic gastritis** → intestinal metaplasia → adenocarcinoma is the classic Correa cascade in this patient because: 1. Pernicious anaemia indicates **autoimmune destruction of parietal cells**. 2. Chronic atrophic gastritis is the consequence. 3. Intestinal metaplasia develops as a reparative response. 4. The adenocarcinoma is **intestinal type** (well-formed glands), not diffuse type. 5. CDX2 loss in metaplasia indicates incomplete intestinal metaplasia with high malignant potential. [cite:Robbins 10e Ch 17]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.